One vision —
a cancer-free future.
Unlike surgery, chemotherapy and radiation, cell and gene therapies harness the power of your immune system to destroy cancer cells without harming healthy tissue. We fund the research that will make this vision a reality.
Help ACGT reach Giving Tuesday donation goal
ACGT has a Giving Tuesday online donation goal with a purpose: for the average number of people diagnosed with cancer each day.
A twist on T-cell therapy for ovarian cancer
Scientists at Moffitt Cancer Center are testing CER T-cell therapy in a phase 1 clinical trial.
Injecting nanoparticles to make in-vivo T-cell therapy
ACGT Research Fellow Matthias Stephan, PhD, is progressing in his project of making an injectable form of cell and gene therapy.
Relationship between cell and gene therapy and the blood-brain barrier and
The blood-brain barrier can impede immune cells and treatment from reaching brain tumors, but there are ways around this wall.
Our direct impact on eradicating all cancer.
Collaborating with partners and funding research fellows, we are transforming cancer treatments today while bringing the world closer to a cure for all cancers tomorrow.
31.5
million dollars awarded to groundbreaking research.
61
research fellows supported.
36
of the top medical institutions funded.
Join forces with the world’s leading researchers to finally identify cures.
Cell and gene therapies harness the power of a patient’s own immune system to destroy cancer cells without harming healthy tissue.
Matthias Stephan, MD, PhD
Fred Hutchinson Cancer Research Center
Advancing pre-clinical strategies that combine principles of bioengineering with gene therapy to improve the effectiveness of therapeutic cancer vaccines.
Stephen Gottschalk, MD
St. Jude Children’s Research Hospital
Fortifying a patient’s immune system to attack and destroy sarcomas along with the blood vessels that support their growth.
Daniel J. Powell, PhD
University of Pennsylvania
Using genetic engineering to engage a patient’s existing immune system and enable it to recognize and destroy ovarian cancer.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Matthias Stephan, MD, PhD
Fred Hutchinson Cancer Research Center
Advancing pre-clinical strategies that combine principles of bioengineering with gene therapy to improve the effectiveness of therapeutic cancer vaccines.
Stephen Gottschalk, MD
St. Jude Children’s Research Hospital
Fortifying a patient’s immune system to attack and destroy sarcomas along with the blood vessels that support their growth.
Daniel J. Powell, PhD
University of Pennsylvania
Using genetic engineering to engage a patient’s existing immune system and enable it to recognize and destroy ovarian cancer.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Stay up-to-date with us and get involved.
Oct 05, 2022
Sep 27, 2022
100% of your donation will advance research to cure all cancers.
Your donation will help develop radical new cell and gene therapies that leverage the body’s own biology and immune system to control and ultimately eradicate cancer. 100% of donations directly support scientists working on breakthrough cancer cell and gene therapy research.
Donate Today